A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities

Peripheral T cell lymphomas (PTCLs) comprise heterogeneous malignancies with limited therapeutic options. To uncover targetable vulnerabilities, we generate a collection of PTCL patient-derived tumor xenografts (PDXs) retaining histomorphology and molecular donor-tumor features over serial xenografting. PDX demonstrates remarkable heterogeneity, complex intratumor architecture, and stepwise trajectories mimicking primary evolutions. Combining functional transcriptional stratification and multiparametric imaging, we identify four distinct PTCL microenvironment subtypes with prognostic value. Mechanistically, we discover a subset of PTCLs expressing Epstein-Barr virus-specific T cell receptors and uncover the capacity of cancer-associated fibroblasts of counteracting treatments. PDXs' pre-clinical testing captures individual vulnerabilities, mirrors donor patients' clinical responses, and defines effective patient-tailored treatments. Ultimately, we assess the efficacy of CD5KO- and CD30- Chimeric Antigen Receptor T Cells (CD5KO-CART and CD30_CART, respectively), demonstrating their therapeutic potential and the synergistic role of immune checkpoint inhibitors for PTCL treatment. This repository represents a resource for discovering and validating intrinsic and extrinsic factors and improving the selection of drugs/combinations and immune-based therapies.

Authors

Institutions

Publication Details

Journal
Cell Reports Medicine
Published
2025-03-27
DOI
https://doi.org/10.1016/j.xcrm.2025.102029
Citations
7
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
7.32

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities

Giuseppina Astone, Elisa de Stanchina, Inna Khodos, Giorgio Inghirami et al.
7 citations
Cell Reports Medicine
CAR-T cell therapy research
7.32
article

A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities

Giuseppina Astone, Elisa de Stanchina, Inna Khodos, Giorgio Inghirami, Brunangelo Falini, Domenico Novero, Robin Foà, Zhaoqi Liu, Roberto Piva, Ruchi P. Patel, Anton Karelin, Nicolás Di Siervi, Danilo Fiore, Wing C. Chan, Lúcio Queiroz, Paola Ghione, Maurilio Ponzoni, Joshua Brody, Claudia Pignataro, Ekaterina Postovalova, Marcello Gaudiano, David M. Weinstock, Valentina Fragliasso, Joo Y. Song, Luca Vincenzo Cappelli, Paul Zumbo, Oliver Elemento, Sanjay S. Patel, Laura Santambrogio, Francesca Zammarchi, Peter Martin, Anastasia Nikitina, Andrew M. Intlekofer, Maria Sorokina, Sandrine Degryse, Simone Gardini, Alexander Bagaev, Rodolfo Machiorlatti, Fabrizio Tabbò, Liron Yoffe, Jia Ruan, Maria Teresa Cacciapuoti, Raúl Rabadán, Enzo Médico, Leandro Cerchietti, Gabriele Macari, A. Moskowitz, Clarisse Kayembe, Enrico Tiacci, Wayne Tam, Ekaterina E. Belova, Francesco Bertoni, Luciana Cafforio, Dmitry Tychinin, Giorgia Zanetti, Jude M. Phillip, Daniil Nikitin, Steven M. Horwitz, Doron Betel, Nahuel Zamponi, Zachary Epstein, Claudio Zanettini, Marco Ruella, Jaspreet Osan, Nikita Kotlov, Viktor Svekolkin, Katerina Tikhonova, Anqi Wang, Xueshuai Han, Chengqi Xu, Olga Kudryashova, Samuel Y. Ng, Abigail Taylor, William C. Chiu, Giovanni Medico, Ruiz Arvin Eric
article en
7 citations

Abstract

Peripheral T cell lymphomas (PTCLs) comprise heterogeneous malignancies with limited therapeutic options. To uncover targetable vulnerabilities, we generate a collection of PTCL patient-derived tumor xenografts (PDXs) retaining histomorphology and molecular donor-tumor features over serial xenografting. PDX demonstrates remarkable heterogeneity, complex intratumor architecture, and stepwise trajectories mimicking primary evolutions. Combining functional transcriptional stratification and multiparametric imaging, we identify four distinct PTCL microenvironment subtypes with prognostic value. Mechanistically, we discover a subset of PTCLs expressing Epstein-Barr virus-specific T cell receptors and uncover the capacity of cancer-associated fibroblasts of counteracting treatments. PDXs' pre-clinical testing captures individual vulnerabilities, mirrors donor patients' clinical responses, and defines effective patient-tailored treatments. Ultimately, we assess the efficacy of CD5KO- and CD30- Chimeric Antigen Receptor T Cells (CD5KO-CART and CD30_CART, respectively), demonstrating their therapeutic potential and the synergistic role of immune checkpoint inhibitors for PTCL treatment. This repository represents a resource for discovering and validating intrinsic and extrinsic factors and improving the selection of drugs/combinations and immune-based therapies.

Cell Reports MedicineVol. 6(4)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), City Of Hope National Medical Center (US), Memorial Sloan Kettering Cancer Center (US), NewYork–Presbyterian Hospital (US), Cornell University (US), University of Perugia (IT), Hospital of the University of Pennsylvania (US), Beijing Institute of Genomics (CN), San Raffaele University of Rome (IT), Lander Institute (IL), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Azienda Ospedaliera di Perugia (IT), Azienda Sanitaria Unità Locale di Reggio Emilia (IT), Presbyterian Hospital (US), Institute of Oncology Research (CH), Addgene (US), Department of Medical Sciences (RU), Adc Therapeutics (Switzerland) (CH), Ospedale Santa Maria (IT), Dana-Farber Cancer Institute (US), Boston Engineering (United States) (US), Lymphoma Research Foundation (US), Torino e-district (IT), Institute for Experimental Endocrinology and Oncology (IT), Azienda Sanitaria Locale CN2 (IT), Candiolo Cancer Institute (IT), Center for Genomic Science (IT), Sidney Kimmel Comprehensive Cancer Center (US), Weill Cornell Medicine (US), University of Turin (IT), University of Naples Federico II (IT), Columbia University (US), University of Pennsylvania (US), Sapienza University of Rome (IT), Repligen (United States) (US), Icahn School of Medicine at Mount Sinai (US)
Leukemia and Lymphoma Society, American-Italian Cancer Foundation, National Natural Science Foundation of China, Ministero dell’Istruzione, dell’Università e della Ricerca, Stand Up To Cancer
Openalex Percentile: Top 3%
CAR-T cell therapy research
7.32
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.